Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

serious AEs, compared with 7 percent and 5 percent of patients in the golimumab 50 mg and golimumab 100 mg groups, respectively. Serious infections were reported in 3 percent, 3 percent and 1 percent of patients, and injection site reactions (ISR) through week 16 occurred in 3 percent, 4 percent and 11 percent of patients in the placebo, golimumab 50 mg and golimumab 100 mg groups, respectively. The most commonly reported ISR was erythema, a redness of the skin due to inflammation. No serious or severe ISRs were reported, and none led to the discontinuation of patients in the study. Antibodies to golimumab were detected in 4 percent of golimumab-treated patients (50 mg and 100 mg).

About the GO-FORWARD Trial

GO-FORWARD, a Phase 3, multi-center clinical trial included 444 patients with active RA. Adult patients with more than four tender and swollen joints, despite methotrexate therapy, were randomly assigned to receive golimumab (50 or 100 mg) plus methotrexate, golimumab 100 mg plus placebo or placebo plus methotrexate at weeks 0, 4, 8, 12, 16 and 20. Data were assessed at weeks 14 and 24. The co-primary endpoints were percentage of patients achieving ACR 20 response at week 14 and improvement from baseline in HAQ at week 24.

Through week 24, 68 percent of patients in both the combined golimumab plus methotrexate groups and the placebo plus methotrexate group experienced at least one AE. Nine percent of patients in the combined golimumab plus methotrexate groups experienced a serious AE compared with 4 percent of patients receiving placebo plus methotrexate. Three percent of patients in the combined golimumab plus methotrexate groups and 1 percent in the group receiving placebo plus methotrexate experienced serious infections. Rates of ISRs were 5 percent in the combined golimumab plus methotrexate groups and 3 percent in the group receiving placebo plus methotrexate. Two percent of golimumab-treated patients developed antibodies. Four patients
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. ... ), a leading global specialty pharmaceutical company, and Rhythm, ... granted an exclusive option to acquire Rhythm,s wholly owned ... a peptide ghrelin agonist, for the treatment of diabetic ... Rhythm has completed a successful Phase 2 trial of ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 WriteResult, ... services – has been working with a team of ... New Haven Farms Community Farming Collaborative to provide electronic ... solution. The study, which started in May, aims ... that provides participants weekly exposure to and participation in ...
(Date:10/22/2014)... Md. , Oct. 22, 2014   Synthetic ... developing novel pathogen-specific therapies for serious infections and diseases, ... has issued a Notice of Allowance for a composition ... its C. difficile program, SYN-004. This is ... SYN-004 in the U.S. and adds to the Company,s ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems ... and Labeling Systems, Table-top Counters) by End-user (Inpatient ... & Trends to 2019” analyzes and studies the ... America, Europe, Asia-Pacific, and the Rest of the ... 30 figures spread through 300 pages and in-depth ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Inc. (Nasdaq: IDIX ) announced today that ... Bank of America 2008 Specialty,Pharmaceuticals Conference on Friday, ... Inn, Long Island, NY., The live and ... under "Calendar of Events" in the Idenix Investor ...
... Partners announced today,that it has updated coverage on ... dollar markets, are progressing through,the clinic at a ... results for,Convivia(TM) sometime in the 3rd quarter of ... (DR) Cysteamine for the treatment of cystinosis in,2010," ...
... July 31 /PRNewswire-FirstCall/ - iNutrition, Inc., (http://www.inutrition.com ) ... its,new all natural line of nutrition bars. Fission ... come in three varieties; Fission Fruit, Fission,Energy, and ... delicious fruits, Fission Bars have no refined sugar, ...
Cached Biology Technology:Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP) 2iNutrition Launches New Fission Fruit Nutrition Bars 2
(Date:10/16/2014)... and Mary,s Virginia Institute of Marine Science have ... Protection Agency to identify the streams and wetlands ... tools to help local governments and citizens conserve ... on a dataset of tidal-marsh observations first gathered ... this historical baseline can today,s researchers accurately map ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
(Date:10/15/2014)... Gutenberg University Mainz (JGU) as a full member, ... maintain a significant nationwide standing in the field ... Johannes Gutenberg University Mainz as a full member ... national and international competition for the best minds ... be proud that Mainz University has been recognized ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... brain and squeeze it into a special chamber the size of ... cerebral spinal fluid and thread both of them with artificial blood ... and other brain cells behave as if they were in a ... that monitor how the cells respond when exposed to minute quantities ...
... Geology: researchers experience an earthquake while studying ... as tooth crown height, is used to track aridity ... terrestrial ecosystem is presented; researchers chronicle the discovery of ... highest wave-energy environments on Earth; and a change in ...
... on the University of California, Berkeley, campus has remained surprisingly ... to create a green wildlife haven within a dense urban ... survey conducted over a six-month period covering the winter of ... journal The Condor . The study, conducted during the ...
Cached Biology News:Vanderbilt-led team to develop 'microbrain' to improve drug testing 2Vanderbilt-led team to develop 'microbrain' to improve drug testing 3Vanderbilt-led team to develop 'microbrain' to improve drug testing 4Vanderbilt-led team to develop 'microbrain' to improve drug testing 5Rubbing boulders, fossil mammal teeth, barrier islands, and a change in volcanic behavior 2Rubbing boulders, fossil mammal teeth, barrier islands, and a change in volcanic behavior 3Rubbing boulders, fossil mammal teeth, barrier islands, and a change in volcanic behavior 4Rubbing boulders, fossil mammal teeth, barrier islands, and a change in volcanic behavior 5Rubbing boulders, fossil mammal teeth, barrier islands, and a change in volcanic behavior 6Rubbing boulders, fossil mammal teeth, barrier islands, and a change in volcanic behavior 7Rubbing boulders, fossil mammal teeth, barrier islands, and a change in volcanic behavior 8Rubbing boulders, fossil mammal teeth, barrier islands, and a change in volcanic behavior 9UC Berkeley survey shows college campuses can make good bird havens 2UC Berkeley survey shows college campuses can make good bird havens 3UC Berkeley survey shows college campuses can make good bird havens 4
... inL10 Workstation from Caliper represents a revolutionary ... the first time the ability to generate ... to changing conditions. In addition, each ... due to changes in temperature, and offers ...
... fully automated systems for a broad range ... for applications ranging from compound logistics, over ... screening, which means it has fully automated ... and follow up studies all at your ...
ID clarifier: non-treated with lid...
... Building on over 20 years of experience ... the Life Sciences, the Freedom EVO platform ... expansion according to future needs. Together with ... system is equipped to successfully operate genomics, ...
Biology Products: